Fluxion Biosciences, a provider of cellular analysis tools for use in life science research and drug discovery applications, announced in December the expansion of its sales and service network into Asia.
President Barack Obama on Dec. 8 issued a directive specifying actions that should be taken to make government agencies better able to engage with the public, including plans to make data and information from federally funded research available for public access.
With life sciences evolving so quickly, bioinformatics research is critical to building information infrastructures that can match that evolution, allow researchers to access data quickly and easily and develop new informatics tools as needed. It is no longer enough to generate the best measurement data; researchers also require the best meaning and insight from that data.
Beginning this issue, our Government Watch section will profile some of the latest legal, legislative, and regulatory developments in the pharma/biotech arenas. In our first month of coverage, we had a veritable grab-bag of stories to sink our teeth into, and settled on a wide range of topics to show our readers the various forms government scrutiny can take: federal oversight, state legislation, state regulation and international regulation, to name a few. Our writers—who are no strangers to reporting on such matters—were eager to hit the ground running and delve into these topics, but were met with an all-too-familiar roadblock: Fear.